Non-enzymatic colorimetric sensor for cardiac Troponin I (cTnI) based on self-assembly of gold nanorods on heparin

Vidya, R.; Alex, Saji

doi:10.1007/s13404-020-00287-w

Cited by 8 publications

(4 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…177 Also, heparin-gold nanorods (H-AuNRs) self-assembly nonenzymatic colorimetric detection for cTnI was reported. 178 Similar to this finding, Bhalla et al have developed aptamer-AuNPs and peptide-AuNPs dual nanoprobes for selective aggregationinduced colorimetric detection of cTnI. 179 Wu et al developed a creatine kinase (CK-MM) biomarker detection using aggregation of cysteamine (Cys) functionalized AuNPs in the presence of ATP.…”

Section: Optical Signaling Readout-based Nanobiosensorsmentioning

confidence: 80%

“…This system performs with a 0.5–20 ng/mL linear range and the limit of detection at 0.3 ng/mL . Also, heparin-gold nanorods (H-AuNRs) self-assembly nonenzymatic colorimetric detection for cTnI was reported . Similar to this finding, Bhalla et al have developed aptamer-AuNPs and peptide-AuNPs dual nanoprobes for selective aggregation-induced colorimetric detection of cTnI .…”

Section: Optical Signaling Readout-based Nanobiosensorsmentioning

confidence: 99%

See 1 more Smart Citation

Optical Nanobiosensor-Based Point-of-Care Testing for Cardiovascular Disease Biomarkers

Vairaperumal,

Huang,

Liu

2023

ACS Appl. Bio Mater.

View full text Add to dashboard Cite

Cardiovascular disease is a global health threat, and detecting cardiac biomarkers is essential for early-stage diagnosis and personalized treatment. Traditional approaches have limitations, but optical nanobiosensors offer rapid, highly selective, and sensitive detection. Optical nanobiosensors generate biosignals that transfer light signals while analytes bind with the bioreceptors. Optical nanobiosensors have advantages such as ease of monitoring, low cost, a wide detection range, and high sensitivity without any interference. An optical nanobiosensor platform is a promising approach for point-of-care cardiac biomarker detection with a low detection limit. This review mainly focuses on the detection of cardiovascular disease biomarkers based on various optical nanobiosensor approaches that have been reported during the last five years, and we have categorized them based on optical signal readouts. A detailed discussion of the classification of cardiovascular disease biomarkers, design strategies of optical biosensors, types of optically active nanomaterials, types of bioreceptors, functionalization techniques, various assay types, and sensing mechanisms is presented. Then, we summarize the optical signaling readout-based various nanobiosensors systems for the detection of cardiovascular disease biomarkers. Finally, we summarize and conclude with the recent development of point-of-care testing (PoCT) for cardiovascular disease biomarkers used in various optical readout techniques.

show abstract

Section: Optical Signaling Readout-based Nanobiosensorsmentioning

confidence: 80%

Section: Optical Signaling Readout-based Nanobiosensorsmentioning

confidence: 99%

Optical Nanobiosensor-Based Point-of-Care Testing for Cardiovascular Disease Biomarkers

Vairaperumal,

Huang,

Liu

2023

ACS Appl. Bio Mater.

View full text Add to dashboard Cite

show abstract

“…More importantly, LOD reached a value as low as 17 pg mL −1 . Compared with other reports related to cTnI determination (Table 1), 13,[37][38][39][40][41][42][43][44][45] the prepared lanthanide-doped NPs-based LFA has the merits of relatively low LOD and wide linear range. As for colorimetry, it is hard to distinguish the intermediate color with the naked eye.…”

Section: Analytical Performance Of Lfa Platformmentioning

confidence: 87%

Highly Sensitive Lanthanide-Doped Nanoparticles-Based Point-of-Care Diagnosis of Human Cardiac Troponin I

Chen¹,

Zhou²,

Zhu³

et al. 2022

IJN

View full text Add to dashboard Cite

Cardiac troponin I (cTnI) has been regarded as a gold standard for early diagnosis and prognosis monitoring of acute myocardial infarction (AMI) in clinical practice. Owing to its low concentration in blood, accurate determination of cTnI often requires high sensitivity. However, current established point-of-care (POC) assays are insufficient to meet clinically analytical requirements due to their low sensitivity. Methods: To this end, we established a highly sensitive and reliable POC lateral flow strip based on lanthanide-doped nanoparticles (NPs) for cTnI determination in human blood samples. The capture of cTnI on the lateral flow strip was performed in a sandwich assay, where Eu 3+ -doped vanadate nanoparticles (GdVO 4 :30% Eu NPs) were used as luminescent probes to allow quantification. Results: Our platform realized the analytical sensitivity enhancement with limit-of-detection (LOD) as low as 17 pg mL −1 for cTnI detection, which was lower than the commercial counterpart; meanwhile, it displayed high specificity, excellent reproducibility and outstanding accuracy for analyzing clinical serum samples. Conclusion: Overall, this strategy provided an ultrasensitive, cost-effective and user-friendly platform for on-site cTnI detection, demonstrating the prospect of lanthanide-doped NPs-based POC diagnosis of disease-related biomarkers.

show abstract

“…Furthermore, AuNRs have been demonstrated to provide a visual detection of cTnI in the case of non-enzymatic colorimetric sensors. Recently, Raj et al conducted a study that implies the aggregation of AuNRs with heparin [ 26 ]. Concretely, CTAB-stabilized AuNRs are exposed to heparin, which, due to electrostatic interaction, induces an aggregation of the AuNRs and, implicitly, a reduction in the LSPR wavelength.…”

Section: Surface Plasmon Resonance-based Biosensorsmentioning

confidence: 99%

Cardiac Troponin Biosensor Designs: Current Developments and Remaining Challenges

Campu

Muresan

Craciun

et al. 2022

IJMS

View full text Add to dashboard Cite

Acute myocardial infarction (AMI) is considered as one of the main causes of death, threating human lives for decades. Currently, its diagnosis relies on electrocardiography (ECG), which has been proven to be insufficient. In this context, the efficient detection of cardiac biomarkers was proposed to overcome the limitations of ECG. In particular, the measurement of troponins, specifically cardiac troponin I (cTnI) and cardiac troponin T (cTnT), has proven to be superior in terms of sensitivity and specificity in the diagnosis of myocardial damage. As one of the most life-threatening conditions, specific and sensitive investigation methods that are fast, universally available, and cost-efficient to allow for early initiation of evidence-based, living-saving treatment are desired. In this review, we aim to present and discuss the major breakthroughs made in the development of cTnI and cTnT specific biosensor designs and analytical tools, highlighting the achieved progress as well as the remaining challenges to reach the technological goal of simple, specific, cheap, and portable testing chips for the rapid and efficient on-site detection of cardiac cTnI/cTnT biomarkers in order to diagnose and treat cardiovascular diseases at an incipient stage.

show abstract

Non-enzymatic colorimetric sensor for cardiac Troponin I (cTnI) based on self-assembly of gold nanorods on heparin

Cited by 8 publications

References 24 publications

Optical Nanobiosensor-Based Point-of-Care Testing for Cardiovascular Disease Biomarkers

Optical Nanobiosensor-Based Point-of-Care Testing for Cardiovascular Disease Biomarkers

Highly Sensitive Lanthanide-Doped Nanoparticles-Based Point-of-Care Diagnosis of Human Cardiac Troponin I

Cardiac Troponin Biosensor Designs: Current Developments and Remaining Challenges

Contact Info

Product

Resources

About